Stocktoria
NewAmsterdam Pharma Co N.V. NAMS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-11-23
Chart by TradingView
2/9
Piotroski F — financial health
8.19
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M |
| Net income | -$203.8M | -$241.6M | -$176.9M | -$22.6M |
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | $10.7M |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M |
| Shareholders' equity | $683.4M | $757.5M | $288.4M | $430.1M |
| Ratios | ||||
| Operating margin | -1002.9% | -386.9% | -1298.6% | -3.5% |
| Net margin | -905.7% | -530.3% | -1255.8% | -22.0% |
| Return on assets | -26.5% | -27.9% | -51.0% | -4.7% |
| Return on equity | -29.8% | -31.9% | -61.4% | -5.3% |
| Current ratio | 7.88 | 8.08 | 6.95 | 13.26 |
| Revenue growth | -50.6% | 223.4% | -86.3% | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.19 (safe)
- Working capital / assets 0.767
- Retained earnings / assets -0.991
- EBIT / assets -0.293
- Equity / liabilities 7.96
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001936258 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.